The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Open, scalable, end-to-end solution to improve diagnostic quality and efficiency
Time to combine innovation, access and technology to deliver positive patient outcomes
Smart-performance, fully biodegradable biopolymer sourced from renewable raw materials
Nearly 5000 executives and more than 350 exhibitors turned out at the largest post-pandemic pharma packaging event
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Two main objectives are: Accelerate novel technologies and products for global markets; and Connect academia and industry, creating synergy for faster advancement of the Bioprotection sector
Subscribe To Our Newsletter & Stay Updated
